Last reviewed · How we verify
Subchondroplasty
Subchondroplasty is a Biologic drug developed by University of Calgary. It is currently in Phase 1 development. Also known as: SCP® (Zimmer).
Subchondroplasty is a medical procedure that involves the use of a porous bone substitute material to treat conditions such as knee osteoarthritis and bone marrow edema. It is typically performed in conjunction with knee arthroscopy, a minimally invasive surgical procedure.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Subchondroplasty |
|---|---|
| Also known as | SCP® (Zimmer) |
| Sponsor | University of Calgary |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
- Acute Cholecystitis
- Arthroscopic Surgery
- Difficulty with dorsiflexion of left foot.
- Increased Knee Pain
- Left elbow pain
- Left knee draining sinus
- Left knee stress fracture lateral femoral condyle and impending OCD lesion
- Medial femoral condyle insufficiency fracture
- Osteoarthritis
- Patient had signs of delirium postoperatively
- Right knee chondromalacia patella with right thigh muscle/tendon strain.
- Stress fracture left foot
Key clinical trials
- SCP® Observational Study of the Knee
- Subchondroplasty for Treatment of Bone Marrow Edema in the Foot and Ankle
- SCP Hip Outcomes Study
- A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Foot/Ankle
- Subchondroplasty® Knee RCT (NA)
- Prospective Evaluation of Subchondroplasty in Advanced Knee Osteoarthritis.
- Subchondroplasty Procedure in Patients With Bone Marrow Lesions
- Evaluation of Subchondroplasty™ for Defects Associated With Bone Marrow Lesions
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subchondroplasty CI brief — competitive landscape report
- Subchondroplasty updates RSS · CI watch RSS
- University of Calgary portfolio CI
Frequently asked questions about Subchondroplasty
What is Subchondroplasty?
Who makes Subchondroplasty?
Is Subchondroplasty also known as anything else?
What development phase is Subchondroplasty in?
What are the side effects of Subchondroplasty?
Related
- Manufacturer: University of Calgary — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: SCP® (Zimmer)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing